WHO classification of tumours of soft tissue and bone. 2020.

Engellau J, Seeger L, Grimer R, et al. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World J Surg Oncol. 2018;16:191.

Article  PubMed  PubMed Central  Google Scholar 

Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275–80.

Article  CAS  PubMed  Google Scholar 

von Borstel D, Taguibao RA, Strle NA, Burns JE. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skelet Radiol. 2017;46:571–8.

Article  Google Scholar 

Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol (Toronto, Ont). 2013;20:e442–7.

Article  CAS  Google Scholar 

Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469:591–9.

Article  PubMed  Google Scholar 

Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18:4415–24.

Article  CAS  PubMed  Google Scholar 

McCarthy CL, Gibbons C, Bradley KM, Hassan AB, Giele H, Athanasou NA. Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab. Clin Sarcoma Res. 2017;7:19.

Article  PubMed  PubMed Central  Google Scholar 

Chawla S, Blay JY, Rutkowski P, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20:1719–29.

Article  CAS  PubMed  Google Scholar 

Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020;33:1321–8.

Article  CAS  PubMed  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2021;34:1899–910.

Article  CAS  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022;35:392–9.

Article  CAS  PubMed  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, et al. Correction to: Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Hum Cell. 2023;36:492.

Article  PubMed  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023;36:1804–12.

Article  CAS  PubMed  Google Scholar 

Adachi Y, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1. Hum Cell. 2024;37:874–85.

Article  CAS  PubMed  Google Scholar 

Adams J, Kauffman M. Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest. 2004;22:304–11.

Article  CAS  PubMed  Google Scholar 

Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–37.

Article  CAS  PubMed  Google Scholar 

Fujino T, Suda K, Koga T, et al. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. J Hematol Oncol. 2022;15:79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology. 2018;72:914–22.

Article  PubMed  Google Scholar 

Forsyth RG, Krenács T, Athanasou N, Hogendoorn PCW. Cell biology of giant cell tumour of bone: crosstalk between m/wt nucleosome H3.3, telomeres and osteoclastogenesis. Cancers (Basel). 2021;13:5119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biermann JS, Chow W, Reed DR, et al. NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Cancer Netw JNCCN. 2017;15:155–67.

Article  PubMed  Google Scholar 

Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev. 2010;36:1–7.

Article  PubMed  Google Scholar 

Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004). Rare Tumors. 2009;1: e52.

Article  PubMed  PubMed Central  Google Scholar 

Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics Rev Publ Radiol Soc North Am. 2013;33:197–211.

Google Scholar 

Perche F, Torchilin VP. Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther. 2012;13:1205–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sant S, Johnston PA. The production of 3D tumor spheroids for cancer drug discovery. Drug Discov Today Technol. 2017;23:27–36.

Article  PubMed  PubMed Central  Google Scholar 

Yafei J, Haoran M, Wenyan J, et al. Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation. J Orthop Transl. 2021;29:106–12.

Google Scholar 

Noguchi R, Osaki J, Ono T, et al. Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning. In Vitro Cell Dev Biol Anim. 2024. https://doi.org/10.1007/s11626-024-00983-3.

Article  PubMed  Google Scholar